{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:34:05Z","timestamp":1777484045161,"version":"3.51.4"},"reference-count":5,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cancer Control"],"published-print":{"date-parts":[[2021,1,1]]},"DOI":"10.1177\/10732748211011954","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T06:03:32Z","timestamp":1620108212000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Carcinogenic NMDA Contamination of Drugs for Heartburn, Hypertension and Diabetes"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1263-6570","authenticated-orcid":false,"given":"Meher Binte","family":"Ali","sequence":"first","affiliation":[{"name":"Dow Medical College, Dow University of Health Sciences, Karachi, Sindh, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"bibr1-10732748211011954","unstructured":"U.S. Food and Drug Administration. What to Know and Do About Possible Nitrosamines in Your Medication. Published 2020. Accessed April 14, 2021. https:\/\/www.fda.gov\/consumers\/consumer-updates\/what-know-and-do-about-possible-nitrosamines-your-medication"},{"key":"bibr2-10732748211011954","unstructured":"U.S. Food and Drug Administration. Control of Nitrosamine Impurities in Human Drugs Guidance for Industry. Published 2020. Accessed April 14, 2021. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/control-nitrosamine-impurities-human-drugs"},{"key":"bibr3-10732748211011954","unstructured":"U.S. Food and Drug Administration. Nostrum Laboratories, Inc. Issues Voluntary Nationwide Recall of Metformin HCl Extended Release Tablets, USP 750 mg, Due to N-Nitrosodimethylamine (NDMA) Content Above the Acceptable Daily Intake (ADI) Limit. Published 2020. Accessed April 14, 2021. https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/nostrum-laboratories-inc-issues-voluntary-nationwide-recall-metformin-hcl-extended-release-tablets"},{"key":"bibr4-10732748211011954","doi-asserted-by":"publisher","DOI":"10.3390\/nu11071687"},{"key":"bibr5-10732748211011954","doi-asserted-by":"publisher","DOI":"10.1097\/NT.0000000000000244"}],"container-title":["Cancer Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748211011954","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10732748211011954","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748211011954","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:22:03Z","timestamp":1777386123000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10732748211011954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":5,"alternative-id":["10.1177\/10732748211011954"],"URL":"https:\/\/doi.org\/10.1177\/10732748211011954","relation":{},"ISSN":["1073-2748","1526-2359"],"issn-type":[{"value":"1073-2748","type":"print"},{"value":"1526-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]},"article-number":"10732748211011954"}}